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that the simulation studies presented by Lin et al. should,
therefore, be interpreted with caution.
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To the Editor: As noted by Marchini and Howie (MH), an
advantage of our maximum likelihood (ML) approach is
that the genotypes of untyped SNPs are inferred from
proper posterior distributions. The two-stage approach,
which ignores the phenotype information in the imputa-
tion of genotypes, can yield biased estimates of genetic
effects near disease loci and consequently reduce power,
especially when the genetic effects are strong. It is difﬁcult
to fully account for the uncertainties of the imputed geno-
types in the two-stage approach, especially if environmen-
tal covariates are involved.
From a frequentist point of view, it is impossible to do
better than the ML approach, which has the highest statis-
tical efﬁciency among all valid methods (that use the same
data and make the same assumptions). The two-stage ap-
proach might produce more accurate results than the ML
approach in certain situations because it allows the use of
sophisticated population-genetics models in the ﬁrst stage.
The ML approach is more robust, in that it estimates the
joint distribution between the untyped SNP and the ﬂank-
ing markers nonparametrically. Although we use a small
number of ﬂanking markers, we search over all subsets ofThe Americﬂanking markers around the untyped SNP and select the
subset that provides the best prediction of genotypes at
the untyped SNP. By searching over all possible subsets of
four SNPs among the 20 SNPs closest to each untyped
HapMap SNP, we can typically obtain Rs2 of 1 for more
than 50% of untyped SNPs and Rs2 of > 0.9 for 80% of un-
typed SNPs. It is unclear how much improvement sophis-
ticated population-genetics models can bring.
MH are absolutely right that our simulation studies did
not evaluate the role of sophisticated population-genetics
models. Indeed, we stated this fact in the Discussion of
our article. Our simulation studies were designed to com-
pare the ML and two-stage approaches when the same
set of ﬂanking markers is used. The results showed the efﬁ-
ciency gain of the ML approach due to the use of the phe-
notype information when inferring unobserved genotypes
and the use of retrospective likelihood for reﬂecting case-
control sampling. When applying the ML method to real
data, we always search over a large region around each un-
typed SNP to ﬁnd a set of ﬂanking markers that provides
the best prediction of genotypes for the untyped SNP.
We are intrigued by the comparisons between SNPMStat
and IMPUTE/SNPTEST reported by MH. However, it is dif-
ﬁcult to draw any ﬁrm conclusion from a small number of
selective data sets. The results for the Rheumatoid Arthritisan Journal of Human Genetics 83, 535–540, October 10, 2008 539
Figure 1. Results of Running SNPMStat
and IMPUTE/SNPTEST on the Simulated
Rheumatoid Arthritis Study Data when
the Reference Panel Contains all of the
HapMap SNPs
The log10 p values under the additive
model for the genotyped and untyped
SNPs are shown in black and red dots,
respectively.study shown in Figure 1 of MH were based on a subset of
the HapMap SNPs that was originally posted on our web-
site for the users to test our software. As mentioned by
MH, we recently updated the reference panel to include
all of the HapMap SNPs. With this more realistic reference
panel, the results of SNPMStat and IMPUTE/SNPTEST are
very similar; see our Figure 1. For this example, SNPMStat
was ten times faster than IMPUTE/SNPTEST. It is unclear
how representative the two examples shown in Figures 2
and 3 of MH are or how robust the results of IMPUTE/
SNPTEST are to the choices of parameters used in the pop-
ulation-genetics model. It does not seem possible for an
imputation method with correct type I error to always pro-
duce p values at untyped SNPs that are much smaller than
those at typed SNPs. The comparisons on the p value scale540 The American Journal of Human Genetics 83, 535–540, Octobemight exaggerate the differences between competing
methods, because a small difference in the test statistic at
the extreme tail(s) of the distribution translates into a sub-
stantial difference in the p value. As noted byMH, it would
be preferable to compare the ML and two-stage approaches
through extensive simulation studies with realistic SNP
landscapes and disease effect sizes.
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